High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy

Introduction: Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti‐HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti‐HER2 treatments.

• Publication year

  2015

• Venue

  Molecular Oncology

• Publication date

  2015-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molonc.2015.09.002PMID 26422389PMCID 4968773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy

  2015cited by this paper
• Quantification of HER 2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded ( FFPE ) Breast Cancer Tissues *

  2015cited by this paper
• Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues*

  2015cited by this paper
• Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

  2015cited by this paper
• Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

  2014cited by this paper
• Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

  2014influential reference
• Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.

  2014influential reference
• Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

  2014cited by this paper
• Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

  2014cited by this paper
• Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

  2013cited by this paper
• Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.

  2013cited by this paper
• HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

  2013cited by this paper
• Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue

  2012cited by this paper
• Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry

  2012cited by this paper
• HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

  2010cited by this paper
• Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

  2009cited by this paper
• Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

  2009cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

  2007cited by this paper
• HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

  2006influential reference
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• What brown cannot do for you

  2006influential reference
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002influential reference
• Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

  2002influential reference
• Automated subcellular localization and quantification of protein expression in tissue microarrays

  2002influential reference
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates.

  2025cites this paper
• Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms

  2025cites this paper
• Insights into Extrachromosomal DNA in Cancer: Biogenesis, Methodologies, Functions, and Therapeutic Potential

  2025cites this paper
• Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session.

  2025cites this paper
• Breaking the dichotomy of HER2: highlighting the flaws of simplifying variables

  2025cites this paper
• Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future

  2024cites this paper
• Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

  2024cites this paper
• Isopimaric acid, an ion channel regulator, regulates calcium and oxidative phosphorylation pathways to inhibit breast cancer proliferation and metastasis.

  2023cites this paper
• Targeting human EGFR 2 (HER2) in salivary gland carcinoma

  2023cites this paper
• Emerging Landscape of Targeted Therapy of Breast Cancers With Low HER2 Protein Expression.

  2023cites this paper
• Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test

  2023cites this paper
• Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests

  2023cites this paper
• PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer

  2023cites this paper
• Clinical Proteomics for Solid Organ Tissues

  2023cites this paper
• Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study

  2023cites this paper
• FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations

  2023cites this paper
• Clinical applications of mass spectrometry‐based proteomics in cancer: Where are we?

  2022cites this paper
• The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions

  2022cites this paper
• Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies

  2022cites this paper
• Relative Quantification of Proteins in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue Using Multiplexed Mass Spectrometry Assays

  2022cites this paper
• Microfluidics for detection of exosomes and microRNAs in cancer: State of the art

  2022cites this paper
• The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies

  2022cites this paper
• High-Field Asymmetric Waveform Ion Mobility Spectrometry and Parallel Reaction Monitoring Increases Sensitivity for Clinical Biomarker Quantitation from Formalin-Fixed, Paraffin-Embedded Tumor Biopsies

  2022cites this paper
• Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine

  2021cites this paper
• Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

  2021cites this paper
• Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.

  2021cites this paper
• Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer

  2021cites this paper
• Characteristics of HER2-Positive Breast Cancer according to HER2 2+/ Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center

  2021cites this paper
• Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications

  2020cites this paper
• Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S

  2020cites this paper
• Applying the New Guidelines of HER2 Testing in Breast Cancer

  2020cites this paper
• Developing a routine lab test for absolute quantification of Her2 in Formalin Fixed Paraffin Embedded (FFPE) breast cancer tissues using Quantitative Dot Blot (QDB) method

  2020cites this paper
• Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

  2020cites this paper
• Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2

  2020cites this paper
• Developing a growing cancer profile database based on quantitative analysis of protein biomarkers in formalin-fixed paraffin-embedded specimens.

  2020cites this paper
• Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using Quantitative Dot Blot (QDB) method

  2020cites this paper
• Evaluation of DNA and RNA quality from archival formalin‐fixed paraffin‐embedded tissue for next‐generation sequencing – Retrospective study in Japanese single institution

  2020cites this paper
• Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice Update Mammakarzinom 2019 Teil 2 –

  2019cites this paper
• Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin

  2019cites this paper
• Drug Combinations in Breast Cancer Therapy

  2019cites this paper
• MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

  2019cites this paper
• Development of a Highly Multiplexed SRM Assay for Biomarker Discovery in Formalin-Fixed Paraffin-Embedded Tissues.

  2019cites this paper
• Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

  2019cites this paper
• Isotopologue Multipoint Calibration for Proteomics Biomarker Quantification in Clinical Practice.

  2019cites this paper
• Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial

  2019cites this paper
• HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

  2019cites this paper
• 3D association of ER, PR and Her2 at protein levels to aid sub-grouping of breast cancer patients in routine clinical practice

  2019cites this paper
• Developing a routine lab test for absolute quantification of Her2 in Formalin Fixed Paraffin Embedded (FFPE) breast cancer tissues using Quantitative Dot Blot (QDB) method

  2019cites this paper
• Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.

  2019cites this paper
• Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

  2019cites this paper
• Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer

  2019cites this paper
• Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

  2019cites this paper
• Parallel Reaction Monitoring-Mass Spectrometry (PRM-MS)-Based Targeted Proteomic Surrogates for Intrinsic Subtypes in Breast Cancer: Comparative Analysis with Immunohistochemical Phenotypes.

  2019cites this paper
• Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

  2019cites this paper
• Update Mammakarzinom 2019 Teil 2 – Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis

  2019cites this paper
• TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes

  2018cites this paper
• Clinical potential of mass spectrometry-based proteogenomics

  2018cites this paper
• HER2-positive breast cancer: Current and new therapeutic strategies.

  2018cites this paper
• Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors.

  2018cites this paper
• Data-Independent Acquisition Mass Spectrometry To Quantify Protein Levels in FFPE Tumor Biopsies for Molecular Diagnostics.

  2018cites this paper
• Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.

  2018cites this paper
• Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor‐2 high expressing salivary duct carcinomas

  2018cites this paper
• Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

  2018cites this paper
• SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin.

  2018cites this paper
• A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

  2018cites this paper
• FISH Panel for Leukemic CTCL.

  2017cites this paper
• Immunotherapy against HER2-positive breast cancers /

  2017cites this paper
• Advances in high-dimensional mass cytometry cell and tissue analyses for translational biomarker discovery

  2017cites this paper
• Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

  2017cites this paper
• Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers

  2017cites this paper
• Basis for molecular diagnostics and immunotherapy for esophageal cancer

  2017cites this paper
• Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

  2017cites this paper
• Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes

  2017cites this paper
• Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification

  2017cites this paper
• “Targeted” Chemotherapy for Esophageal Cancer

  2017cites this paper
• Breast cancer diagnosis – role of biomarkers

  2017cites this paper
• Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound.

  2017cites this paper
• The aryl hydrocarbon receptor in the crossroad of signalling networks with therapeutic value.

  2017cites this paper
• How may targeted proteomics complement genomic data in breast cancer?

  2017cites this paper
• Molecular pathology of cancer: how to communicate with disease

  2016cites this paper
• Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

  2016cites this paper
• Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

  2016cites this paper
• MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma

  2016cites this paper
• The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis

  2016cites this paper
• Glutathione S transeferase as a prediagnostic tool and tumor marker in breast cancer

  2016cites this paper
• The search for simplicity: is this compatible with precision medicine?

  2016cites this paper
• Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance.

  2016cites this paper
• High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy

  2015cites this paper